The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the ongoing expansion of the regenerative medicine sector, Instinct Bio has completed its merger with Relativity Acquisition Corp to become a publicly traded entity. The company's shares are scheduled to commence trading on the Nasdaq Stock Market under the ticker BIOT starting July 24, 2026. This business combination is designed to provide the company with access to public capital markets to fund the development of its regenerative medicine and longevity platform.
The debut follows the establishment of a pro forma enterprise value for the combined company of approximately $288 million. Through this merger, the firm will operate as a global platform specializing in cell-based therapies, evolving from its Tokyo-based origins into a U.S.-listed innovator. According to reports, this listing represents a defining moment in the company's institutional evolution and its transition toward global operations.
Based on market data, specific price levels for the instrument are currently unavailable prior to the official trading launch on July 24, 2026. Investors will be watching the company's ability to maintain Nasdaq listing standards and realize anticipated merger benefits amid competition in the biotech sector. Current economic calendars show no direct upcoming catalysts for the company within the immediate seven-day window following its debut.